Guggenheim analyst Vamil Divan lowered the firm’s price target on Valneva (VALN) to $14 from $15 and keeps a Buy rating on the shares. Valneva released detailed Q1 results and provided a corporate update, then announced that the European Medicines Agency is temporarily suspending the use of Valneva’s chikungunya vaccine Ixchiq in people over 65 years old as part of the ongoing review of serious adverse events, notes the firm, which is modestly lowering its Ixchiq revenue estimates to account for this new potential safety concern.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva SE Reports Strong Q1 2025 Revenue Growth
- Valneva Reports Strong Q1 2025 Results and Advances Vaccine Portfolio
- Valneva says EMA started Ixchiq review after reports of SAEs
- Valneva’s Chikungunya Vaccine Use Suspended for Elderly Amid Safety Concerns
- Valneva’s Chikungunya Vaccine Receives Updated ACIP Recommendation Amid Safety Review
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue